清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Association of Rituximab With Risk of Long-term Cardiovascular and Metabolic Outcomes in Patients With Pemphigus

医学 硫唑嘌呤 内科学 美罗华 人口 相对风险 外科 疾病 置信区间 环境卫生 淋巴瘤
作者
Khalaf Kridin,Noor Mruwat,Ralf J. Ludwig
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:159 (1): 56-56 被引量:10
标识
DOI:10.1001/jamadermatol.2022.5182
摘要

The association of different therapeutic approaches with long-term cardiovascular and metabolic outcomes in patients with pemphigus remains to be precisely evaluated.To assess the risk of long-term cardiovascular and metabolic outcomes and all-cause mortality in patients with pemphigus managed by rituximab compared with those receiving treatment with first-line corticosteroid-sparing agents (azathioprine and mycophenolate mofetil [MMF]).A global population-based retrospective cohort study compared 961 patients with pemphigus that was managed with rituximab with those treated with azathioprine or MMF (n = 961) regarding the risk of several cardiovascular and metabolic outcomes. Propensity score matching was performed to optimize comparability. Patients were enrolled from the Global Collaborative Network of TriNetX platform.Risk of myocardial infarction, stroke, peripheral vascular disease, pulmonary embolism, hypertension, hyperlipidemia, type 2 diabetes, obesity, osteoporosis, and avascular bone necrosis.Of 1602 participants, 855 (53.4%) were women and 747 (46.6%) were men; the mean (SD) age was 54.8 (16.6) years for those treated with rituximab and 54.4 (18.2) years for those treated with azathioprine or MMF. Compared with those treated by azathioprine/MMF, patients treated with rituximab experienced a lower risk of myocardial infarction (relative risk [RR], 0.45; 95% CI, 0.24-0.86; P = .01), stroke (RR, 0.42; 95% CI, 0.26-0.69; P < .001), peripheral vascular disease (RR, 0.47; 95% CI, 0.28-0.79; P = .003), hypertension (RR, 0.48; 95% CI, 0.38-0.63; P < .001), hyperlipidemia (RR, 0.45; 95% CI, 0.32-0.64; P < .001), type 2 diabetes (RR, 0.63; 95% CI, 0.51-0.77; P < .001), obesity (RR, 0.49; 95% CI, 0.34-0.72; P < .001), and osteoporosis (RR, 0.46; 95% CI, 0.30-0.71; P < .001). The all-cause mortality was comparable between patients in both groups (hazard ratio, 0.94; 95% CI, 0.62-1.43; log-rank P = .77).The results of this cohort study suggest that rituximab was associated with protection against long-term cardiovascular and metabolic outcomes compared with conventional immunosuppressants. This agent might be particularly preferred in individuals with preexisting cardiovascular and metabolic risk factors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
寒战完成签到 ,获得积分10
刚刚
沐浠完成签到 ,获得积分10
12秒前
salty完成签到 ,获得积分10
21秒前
桐桐应助123采纳,获得10
31秒前
Shandongdaxiu完成签到 ,获得积分10
34秒前
HCKACECE完成签到 ,获得积分10
41秒前
Vicky完成签到 ,获得积分10
42秒前
45秒前
丰富的绮山完成签到,获得积分10
45秒前
烟花应助科研通管家采纳,获得30
49秒前
Akim应助科研通管家采纳,获得30
49秒前
123发布了新的文献求助10
51秒前
段采萱完成签到 ,获得积分10
52秒前
Ava应助123采纳,获得30
1分钟前
leng完成签到 ,获得积分10
1分钟前
dragonhmw完成签到 ,获得积分10
1分钟前
烟花应助依居采纳,获得10
1分钟前
玉一一完成签到 ,获得积分10
1分钟前
哈拉斯完成签到,获得积分10
1分钟前
1分钟前
依居发布了新的文献求助10
1分钟前
蓝胖胖蓝完成签到,获得积分10
1分钟前
1分钟前
稀松完成签到,获得积分10
1分钟前
2分钟前
陌子完成签到 ,获得积分10
2分钟前
zjq完成签到 ,获得积分10
2分钟前
2分钟前
飞云完成签到 ,获得积分10
2分钟前
铁妹儿完成签到 ,获得积分10
2分钟前
SHD完成签到 ,获得积分10
3分钟前
煜琪完成签到 ,获得积分10
3分钟前
高贵逍遥完成签到 ,获得积分10
3分钟前
wyh295352318完成签到 ,获得积分10
3分钟前
jie完成签到 ,获得积分10
3分钟前
さくま完成签到,获得积分10
3分钟前
啥时候能早睡完成签到 ,获得积分10
3分钟前
dbdxyty完成签到,获得积分10
3分钟前
沉香如兰完成签到,获得积分10
3分钟前
幸福安康完成签到 ,获得积分10
4分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052644
求助须知:如何正确求助?哪些是违规求助? 2709863
关于积分的说明 7418252
捐赠科研通 2354395
什么是DOI,文献DOI怎么找? 1246007
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921